<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>28416232</identifier>
<setSpec>1578-8989</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Ramos-Lora, Manuel</dc:author>
<dc:author>Maraver-Zamora, Marta</dc:author>
<dc:author>Correia-Varela-Almeida, Antonio</dc:author>
<dc:author>García-García, Federico</dc:author>
<dc:author>Cabello-Fernández, Ana</dc:author>
<dc:author>Romero-Herrera, Gema</dc:author>
<dc:author>Cabanillas-Casafranca, Manuel</dc:author>
<dc:author>Jiménez-Macías, Fernando Manuel</dc:author>
<dc:description xml:lang="en">INTRODUCTION AND OBJECTIVE Inclusion of direct-acting antivirals into clinical practice in patients with chronic HCV (CHC) has been a milestone in medicine. PATIENTS AND METHODS Analytical, prospective study, involving 126 patients with chronic HCV treated with direct-acting antivirals. Efficacy and safety of treatment and factors associated with failure treatment were evaluated. RESULTS Age 54±10. Male (70%). Cirrhosis (60%). Distribution according to genotypes: G1a (31%), G1b (42%); G3 (14%); G4 (13%). Child-Pugh B and C (n=15). Naïve (56%). SVR rate was (87.3%): Child-A (91%), Child-B (75%) and Child-C (60%). The best cure rates were achieved with a 3D/2D±ribavirin (SVR=97.4%;n=39) and sofosbuvir/ledipasvir±ribavirin (RVS=93.1%; n=29) combination. An SVR rate of &lt;90% was achieved with sofosbuvir+simeprevir±ribavirin (SVR=88%, n=25), simeprevir+daclatasvir±ribavirin 73%, n=15). The association of ribavirin to these last three therapeutic options (n=19) improved cure rates (SVR=94.7%, 18/19) compared to its absence (n=39;SVR=77%). Improvement in MELD (40%). Output transplant list (20%). Substitutions associated with resistors NS3: G1a (positions 80K; n=5); G1b and G4 (position 168 and 36; n=4), while for NS5a: G1a (position 30; n=2) and G1b and G3 (position 93; n=3). Variables associated with failure in multivariate analysis (p&lt;0.05): presence of ascites, G3 and ribavirin dosage&lt;600mg/day. DISCUSSION The presence of genotype 3, ascites or dosage of ribavirin&lt;600mg/day were associated with higher failure rates. The use of ribavirin&gt;600mg/day in cirrhotic G1 or G3, who will be treated with sofosbuvir+simeprevir or daclatasvir is recommended where no baseline resistance test is available.</dc:description>
<dc:type>Journal Article</dc:type>
<dc:language>es</dc:language>
<dc:subject>Resistance</dc:subject>
<dc:subject>Cirrhosis</dc:subject>
<dc:subject>Cirrosis</dc:subject>
<dc:subject>Antiviral</dc:subject>
<dc:subject>Hepatitis C</dc:subject>
<dc:subject>Resistencia</dc:subject>
<dc:date>2017 Nov 09 </dc:date>
<dc:title xml:lang="es">Experiencia en práctica clínica real con los nuevos antivirales de acción directa en hepatitis crónica C.</dc:title>
<dc:title xml:lang="en">Experience in real clinical practice with new direct acting antivirals in chronic hepatitis C.</dc:title>
<dc:publisher>Medicina clinica</dc:publisher>
</metadata>
</record>
</pubmed-document>
